Baker Stuart G, Kramer Barnett S
Biometry Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA.
Biomark Insights. 2020 Aug 4;15:1177271920946715. doi: 10.1177/1177271920946715. eCollection 2020.
We review simple methods for evaluating 4 types of biomarkers. First, we discuss the evaluation of surrogate endpoint biomarkers (to shorten a randomized trial) using 2 statistical and 3 biological criteria. Second, we discuss the evaluation of prognostic biomarkers (to predict the risk of disease) by comparing data collection costs with the anticipated net benefit of risk prediction. Third, we discuss the evaluation of predictive markers (to search for a promising subgroup in a randomized trial) using a multivariate subpopulation treatment effect pattern plot involving a risk difference or responders-only benefit function. Fourth, we discuss the evaluation of cancer screening biomarkers (to predict cancer in asymptomatic persons) using methodology to substantially reduce the sample size with stored specimens.
我们回顾了评估4种生物标志物的简单方法。首先,我们讨论使用2种统计学标准和3种生物学标准来评估替代终点生物标志物(以缩短随机试验)。其次,我们通过比较数据收集成本与风险预测的预期净效益,来讨论预后生物标志物(预测疾病风险)的评估。第三,我们使用涉及风险差异或仅针对反应者的获益函数的多变量亚组治疗效应模式图,来讨论预测性标志物(在随机试验中寻找有前景的亚组)的评估。第四,我们讨论使用大幅减少存储标本样本量的方法来评估癌症筛查生物标志物(预测无症状人群中的癌症)。